MedTrace Logo

Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer

NCT00056095 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2021-02-24

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.

PURPOSE: This phase II trial is studying how well allogeneic stem cell transplant works in treating patients with metastatic kidney cancer.

Conditions

Interventions

BIOLOGICAL

therapeutic allogeneic lymphocytes

DRUG

cyclophosphamide

DRUG

cyclosporine

DRUG

fludarabine phosphate

PROCEDURE

allogeneic bone marrow transplantation

PROCEDURE

peripheral blood stem cell transplantation

Sponsors & Collaborators

  • UNICANCER

    lead OTHER

Principal Investigators

  • Didier Blaise, MD · Institut Paoli-Calmettes

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-11-04
Primary Completion
2008-02-13
Completion
2016-08-17

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00056095 on ClinicalTrials.gov